2024 Ash Meeting Abstracts Incorporated. Measurable residual disease in aml in 2024 and beyond 621. Disease burden and minimal residual disease in prognosis and treatment:
Measurable residual disease in aml in 2024 and beyond 621. The final oral presentation and clinical poster will be available after the.